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296* Transient low fecal elastase levels in two CF infants with G551D
following newborn screening
G. Keelty1, S.J. Mayell1, E.F. Burrows1, R. Watling1, K.W. Southern2. 1Royal
Liverpool Children’s Hospital, Liverpool, United Kingdom; 2University of
Liverpool, Institute of Child Health, Liverpool, United Kingdom
Introduction: Measurement of fecal elastase (FE) provides a useful non-invasive
tool to assess pancreatic function. For CF infants recognised following newborn
screening (NBS) in our region, we have measured FE at diagnosis and approximately
3 monthly if high or intermediate. Together with clinical assessment, this guides
instigation of pancreatic enzyme replacement therapy (PERT).
Method: Retrospective review of early PERT in light of clinical assessment and
FE measurement.
Results: Ten infants were identiﬁed through NBS since 2007. In six infants, clinical
assessment (weight loss and loose fatty stools) suggested pancreatic insufﬁciency
(PI). Subsequent FE measurement supported this (FE< 15mg/g). In 4 infants,
clinical assessment was less clear. Two are thriving with no suggestion of PI
(FE> 500 and 137mg/g) and PERT has not been instigated. In two infants, PERT
was commenced as a result of clinical assessment and a low FE. One infant had
complicated neonatal surgery for a non-CF problem, FE levels were 188mg/g at
diagnosis, 370mg/g and >500mg/g at 9 and 11 months respectively. In the second
infant, FE levels were 91mg/g at diagnosis, 196mg/g at 4 months and >500mg/g
at 11 months. In both infants PERT was subsequently discontinued. Both of these
infants were compound heterozygous for G551D.
Conclusions: Measurement of FE can guide CF teams in the need for PERT in
infants following NBS, however continued monitoring is necessary. In our small
series we report two infants (both with G551D) in whom transient low FE levels
have returned to normal.
297* Reproducibility of coefﬁcient of fat absorption (CFA) in cystic
ﬁbrosis patients with pancreatic insufﬁciency
D. Borowitz1, M. Campion2, C. Stevens2, L. Brettman2, Liprotamase 726 Study
Group. 1State University of New York at Buffalo, Buffalo, NY, United States;
2Alnara Pharmaceuticals, Cambridge, MA, United States
Coefﬁcient of Fat Absorption (CFA) is a measure of efﬁcacy of pancreatic enzyme
replacement therapy (PERT) for pancreatic insufﬁciency (PI). Change in CFA is
the efﬁcacy endpoint in studies of PERT. We determined reproducibility of CFA in
CF patients with PI. We obtained a baseline CFA (b-CFA) off PERT in subjects
who participated in a Phase III randomized withdrawal design study of liprotamase
(www.clinicaltrials.gov). Subjects then took liprotamase in an open-label phase prior
to randomization to either liprotamase or placebo. A double-blind CFA (db-CFA)
was performed under identical study conditions 22−31 days after b-CFA. Subjects
ate a controlled 72-hour diet (100 grams of fat/day); stool collection was demarcated
with oral blue dye. Foods were identical and subjects on acid suppression remained
on during both study periods. 200 subjects were screened; 138 subjects were
randomized. 68 subjects were randomized to placebo; 2 withdrew prior to db-CFA.
Mean b-CFA= 49.5 (SD= 17.9; range = 11.7, 87.3); mean db-CFA= 49.5 (SD 21.87;
range 1.8, 91). 50% of the variance of the db-CFA was explained by the b-CFA
(Pearson r = 0.69, Spearman r = 0.73, p< 0.0001). Change in CFA was normally
distributed but 20% (13/66) subjects had >20% difference (maximum = 44%)
between the b-CFA and db-CFA. Reproducibility of CFA in CF patients off PERT
was variable even under strict research conditions. This variability may be due to
changes in gastric, biliary, intraluminal, mucosal or motility factors that impact fat
absorption or related to the inherent difﬁculties in performing CFA and may effect
the magnitude of change in CFA in different placebo controlled studies and study
designs.
298 Antibiotic therapy does not improve fat digestion and absorption
in cystic ﬁbrosis
A. Lisowska1, A. Pogorzelski2, G. Oracz3, W. Skorupa4, S. Cofta5, J. Socha3,
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Tuberculosis & Lung Diseases, Department of Bronchology & Cystic Fibrosis,
Rabka, Poland; 3Child Memorial Health Institute, Department of Pediatric
Gastroenterology, Hepatology & Immunology, Warszawa, Poland; 4National
Tuberculosis and Lung Diseases Research Institute, 1st Clinic of Lung Diseases,
Warszawa, Poland; 5University of Medical Sciences, Department of Respiratory
Medicine, Poznan, Poland; 6 Institute of Biomedicine, Biocenter of Oulu, University
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Antibiotic therapy in the cystic ﬁbrosis mouse model resulted in reduced bacterial
load of intestine and signiﬁcant body weight gain. The effect may be linked to the
improvement of intestinal digestion and absorption. Therefore, we have aimed to
assess the inﬂuence of routinely applied antibiotic therapy in CF patients on fat
digestion and absorption.
Material and Methods: Twenty pancreatic insufﬁcient CF patients aged 6
to 30 years entered the study. Inclusion criteria comprised conﬁrmed exocrine
pancreatic insufﬁciency (fecal elastase-1 concentration <100mcg/g of stool) and
bronchopulmonary exacerbation demanding antibiotic therapy. Fourteen subjects
were treated intravenously with ceftazidime and amikacin, six patients orally with
ciproﬂoxacin. In all studied subjects 13C-labelled mixed triglyceride breath test
(MTG-BT) was performed for the assessment of fat digestion and absorption
efﬁciency.
Results: Cumulative percentage dose recovery (CPDR) before (mean±SEM:
10.1±4.1, median: 3.3) and after (mean±SEM: 10.7±3.6, median: 6.4) intra-
venous antibiotic therapy did not differ. Similarly, no differences in CPDR before
(mean±SEM: 4.7±0.9, median: 3.4) and after (mean±SEM: 5.9±1.1, median: 5.4)
oral antibiotic treatment were stated.
Conclusions: Routinely applied antibiotic therapy does not result in improvement
of fat digestion and absorption.
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299 Switching CF patients from previous pancreatic enzyme
replacement therapy to ZENPEP™ (pancrelipase delayed-release
capsules) improves symptom control of exocrine pancreatic
insufﬁciency (EPI)
J.E. Heubi1, C. Straforini2, R. Thieroff-Ekerdt3. 1Cincinnati Children’s Hospital
Medical Center, Cincinnati, OH, United States; 2Eurand S.p.A., Clinical and
Development Operations, Pessano Con Bornago, Italy; 3Eurand Pharmaceuticals,
Inc., Clinical & Regulatory Affairs, Yardley, PA, United States
Background: ZENPEP™, an FDA-approved pancrelipase formulation with 100%
of the labeled lipase claim without overage, has been shown to signiﬁcantly improve
steatorrhea (72 hr-CFA) in a phase III randomized, double-blind, placebo-controlled,
cross-over study of 34 CF patients with EPI.
Objective: To compare Total Symptom Score Index [TSI] with ZENPEP after
switching from unapproved pancreatic enzyme replacement therapy (PERT [e.g.,
Creon, Ultrase, Pancrecarb]) in a post hoc analysis of 31 evaluable patients.
Methods: Eligible patients had to discontinue gastric acid modiﬁers and were
switched from unapproved PERT to ZENPEP and dose-titrated in a stabilization
period according to symptom control of EPI for 6−9 days prior to randomization to
ZENPEP or placebo. TSI was calculated from individual patient-reported symptoms
of stool consistency, bloating, ﬂatulence, pain, and visible oil in stool.
Results: At comparable doses, patients experienced signiﬁcant and rapid symptom
improvement during the stabilization period when switched from previous PERT
(mean dose 5100U lipase/kg/day) to ZENPEP (mean dose 4600U lipase/kg/day).
Mean TSI signiﬁcantly decreased from 11.2(±15.8) on previous PERT to 4.3(±4.0)
after 7 days of ZENPEP treatment (P < 0.004). Symptom improvement was ob-
served by Day 2 and was signiﬁcant at Day 4 (P = 0.017). Variability of symptom
severity was markedly diminished during ZENPEP treatment.
Conclusions: At a similar average daily lipase dose and without concomitant use
of gastric acid modiﬁers, ZENPEP provided enhanced symptom control of EPI in
CF patients when switched from other PERT.
